Latest Breaking News On - Daniel petrylak - Page 1 : comparemela.com

ASCO 2024: ARV-766, a PROTAC Androgen Receptor Degrader, in mCRPC: Initial Results of a Phase 1/2 Study

ASCO 2024: ARV-766, a PROTAC Androgen Receptor Degrader, in mCRPC: Initial Results of a Phase 1/2 Study
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United statesDaniel petrylakDanielp petrylakZachary klaassenYale school of medicineGeorgia cancer centerAmerican society of clinical oncologySmilow cancer centerClinical oncologyYale schoolNew havenUrologic oncologistAssociate professorAnnual meeting

New research and treatment advances from Yale Canc

New research and treatment advances from Yale Canc
newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.

United statesPamela kunzMichael cecchiniPat lorussoDaniel petrylakBarbara burtnessRoy herbstFerrigno guajardoYale cancer centerYale school of medicineAmerican society of clinical oncologyYale schoolAmerican societyClinical oncologyCancer careFrom comfort

New Research and Treatment Advances From Yale Canc

New Research and Treatment Advances From Yale Canc
newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.

United statesDaniel petrylakPat lorussoMichael cecchiniPamela kunzFerrigno guajardoRoy herbstBarbara burtnessYale school of medicineYale cancer centerAmerican society of clinical oncologyYale schoolAmerican societyClinical oncologyCancer careFrom comfort

Dr Petrylak on the Shifting Role of Avelumab Maintenance in Metastatic Urothelial Cancer

Daniel Petrylak, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the use of avelumab maintenance in urothelial cancer.

Daniel petrylakYale school of medicineGenitourinary oncologyYale school

Dr Petrylak on Treatment With Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

Daniel Petrylak, MD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.

Daniel petrylakYale school of medicineMedical oncologyGenitourinary oncologyYale schoolYale cancer centerOnclive tvUrothelial carcinoma